BioSpace News Archive

Natus Medical Incorporated announced its first quarter revenue estimate and withdrew its full year 2020 guidance.

Company to Host Audio Webcast and Conference Call of First Quarter 2020 Results on May 11, 2020

P4 Diagnostix® Network has announced they have submitted their LDT for COVID-19 based upon the FDA EUA approved ThermoFisher TaqPath RT-PCR COVID-19 Combo Kit.

GlycoMimetics, Inc. announced that the compensation committee of the Company’s Board of Directors approved the grant on April 1, 2020 of non-qualified stock option awards to purchase an aggregate of 40,600 shares of its common stock to two new employees.

Atreca, Inc., a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, announced that it will participate in two upcoming investor conferences

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported interim results from the ongoing ACROBAT Edge Phase 2 trial.

Luminex Corporation announced 1st quarter 2020 revenues of just over $90 million, up approximately 10% over the 1st quarter of 2019 and approximately 8% above the top end of its previously communicated 1st quarter revenue guidance range of $82 to $84 million.

Timber Pharmaceuticals LLC announced the company has been awarded the second tranche of $500,000 of the $1.5 million grant from the U.S. Food & Drug Administration Office of Orphan Products Development Orphan Products Clinical Trials Grants Program after reaching certain clinical milestones in the development of TMB-001.

Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders

AACC is pleased to announce that the organization will be able to preserve the complete 2020 AACC Annual Scientific Meeting & Clinical Lab Expo experience for its attendees by moving the meeting to December 13-17, 2020.